Summary of COVID-19 dalcetrapib studies
Hide extended summaries
RCT 227 COVID-19 outpatients with symptom onset within 5 days, showing no signficiant benefits with dalcetrapib treatment.
May 2021, NCT04676867, https://clinicaltrials.gov/study/NCT04676867, https://c19p.org/kallend
1. Kallend et al., A Double-blind, Placebo-controlled, Phase 2a Proof-of-concept Trial of Dalcetrapib in Patients With Confirmed Mild to Moderate COVID-19
227 patient dalcetrapib early treatment RCT: 134% higher mortality (p=1), 134% higher ventilation (p=1), 139% higher need for oxygen therapy (p=0.68), and 37% higher hospitalization (p=1).RCT 227 COVID-19 outpatients with symptom onset within 5 days, showing no signficiant benefits with dalcetrapib treatment.
May 2021, NCT04676867, https://clinicaltrials.gov/study/NCT04676867, https://c19p.org/kallend
Please send us corrections, updates, or comments.
c19early involves the extraction of 200,000+ datapoints from
thousands of papers. Community updates
help ensure high accuracy.
Treatments and other interventions are complementary.
All practical, effective, and safe
means should be used based on risk/benefit analysis.
No treatment or intervention is 100% available and effective for all current
and future variants.
We do not provide medical advice. Before taking any medication,
consult a qualified physician who can provide personalized advice and details
of risks and benefits based on your medical history and situation. IMA and WCH
provide treatment protocols.
Thanks for your feedback! Please search before submitting papers and note
that studies are listed under the date they were first available, which may be
the date of an earlier preprint.